Preclinical studies have shown that low, non-cytotoxic doses of DAC induce targeted demethylation and upregulate tumour-suppressive genes such as NOTCH1, thereby restoring transcriptional activity and impairing tumour progression [33]. Here, NOTCH1 is linked to neoplasm.